Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q2 FY26 Earnings Presentation
25 slides from Balaxi Pharmaceuticals's earnings presentation, Nov 14, 2025
Slide 1: Cover letter to NSE: Investor Presentation
Date:14.11.2025 To, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, Plot No C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 NSE Symbol: BALAXI Dear Sir/Madam, Subject: Investor Presentation In compliance with Regulation 30 of SEBI (Listing Obligations an
Slide 2: Branded IPR-driven Pharma Player in Frontier Markets
Branded IPR-driven Pharma Player in Frontier Markets Investor Presentation
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, technological risks, and many other factors that could cause our actual
Slide 4: Contents
Contents 04 Corporate Snapshot 17 Financial Highlights 23 Strategic Roadmap 3
Slide 5: Bridging the Supply Gap in Frontier Markets
Bridging the Supply Gap in Frontier Markets Branded IPR-based pharma Presence in OTC segments including company strong branded generics portfolio Frontier markets leadership in Targeting top-2 position in each Latin America and Africa geography Vast portfolio across diverse Backed by deep distributi
Slide 6: Successful Produce, Stock, Sell Business Model
Successful Produce, Stock, Sell Business Model Established operations: Guatemala (Latin America), Dominican Republic (Caribbean) and Expansion initiated: Markets Angola (Africa) Ecuador, Chile (Latin America) New operations: Hondurus, El Salvador,and Nicaragua 935 product registrations in Seven coun
Slide 7: Key Success Factors
Key Success Factors Market Selection Methodology Focus on countries with high-potential economic growth framework Identify non-English speaking countries with similar characteristics Low competitive intensity and potential to establish top-2 position On-ground feedback mechanism allows deep
Slide 8: Transition from “Asset Light” to “Asset Right”
Transition from “Asset Light” to “Asset Right” Marketing and Market Research Product Product Manufacturing Distribution Identification Registration Existing Operations New Manufacturing Unit As a part of its corporate evolution, Balaxi has moved its business model from ‘Asset Light’ to ‘Asset Right’
Slide 9: Investment in Manufacturing Facilities
Investment in Manufacturing Facilities Company’s first pharmaceutical formulation manufacturing unit General Oral Solid Dosage (OSD) formulations Targeting demand for high quality products in Latin American markets Allows full backward integration of supply chain Plant Qualification and Validation i
Slide 10: Glimpse of Company’s first Formulation Facility
Glimpse of Company’s first Formulation Facility: 9
Slide 11: Glimpse of Company’s first Formulation Facility
Glimpse of Company’s first Formulation Facility: 10
Slide 12: Glimpse of Company’s first Formulation Facility
Glimpse of Company’s first Formulation Facility: 11
Slide 13: Global Footprint
Global Footprint Portugal China Existing Market Dominican Republic India Targeted Expansion Guatemala Honduras Product Sourcing Regions El Salvador Nicaragua Ecuador Angola Chile Existing/targeted markets have aggregate GDP of $ 400 billion and pharma imports of $ 6 billion 12
Slide 14: Key Milestones
Key Milestones Started business supplying white labelled products to customers in Africa Diversified supply chain by Products were sourced from sourcing pharma products Set-up central distribution WHO GMP certified plants from WHO GMP certified warehouse in Guatemala, based in India manufacturers in
Slide 15: Corporate Structure
Corporate Structure Balaxi Pharmaceuticals Limited Balaxi Global DMCC, Dubai (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi Healthcare Healthcare Balaxi Healthcare Balaxi Healthcare Healthcare Healthcare Healthcare Dominica Guatemala Angola LDA EL Salvador Honduras Healthcare Nicaragua Angola LDA C
Slide 16: Experienced Board of Directors
Experienced Board of Directors Ashish Maheshwari Minoshi Maheshwari Kunal Bhakta Chairman & Managing Director Non-Executive Director Independent Director Founder of the company, first Co-founder, 20 years of Chartered Accountant with 15 years’ generation entrepreneur, rich experience with Balaxi exp
Slide 17: Dynamic Leadership Team
Dynamic Leadership Team Ashish Maheshwari Amol Mantri Chairman & Managing Director CFO Founder of the company, first generation Qualified Chartered Accountant and Certified Public entrepreneur, qualified Chartered Accountant Accountant from USA Commenced business by supplying white labelled Associat
Slide 18: Financial Highlights
FINANCIAL HIGHLIGHTS MIM emg Balaxi
Slide 19: Management’s Comments – Q2 FY26 Performance
Management’s Comments – Q2 FY26 Performance “Q2 FY26 was a challenging quarter, with revenue declining to ₹56.17 crore from ₹77.38 crore in the same period last year, reflecting a 27% YoY decrease. The decline was primarily driven by softer market demand, pressure on working capital, and shipping an
Slide 20: Quarterly Financial Performance - Consolidated
Quarterly Financial Performance - Consolidated Particulars (INR Crore) Q2 FY26 Q2 FY25 YoY Revenue 56.17 77.38 (27.4%) Gross Profit 27.14 33.21 (18.3%) Gross Margin % 48.3% 42.9% +540 bps EBITDA 1.17 10.59 (88.9%) EBITDA Margin 2.1% 13.7% (1158 bps) Profit After Tax 0.21 4.59 (95.4%) PAT Margin % 0.
Slide 21: Pharma Product Mix – Q2 FY26
Pharma Product Mix – Q2 FY26 Geographies Products Shareholders’ Debt Fixed Assets Working Capital 37% Funds Africa* 40% Branded LATM** Generics 63% 60% Dosage Forms Therapeutic Areas 16% Tablets Antibiotics 36% Injectables Analgesic 42% 41% 16% Liquids Anti-malaria Capsules Others 11% Others 8% 15%
Slide 22: Financial Performance (Consolidated): FY25
Financial Performance (Consolidated): FY25 Particulars (INR Crore) FY25 FY24 YoY Revenue 292.56 241.29 21.2% Gross Profit 126.86 112.61 12.6% Gross Margin % 43.4% 46.7% -331 bps EBITDA 33.50 44.08 (24%) EBITDA Margin % 11.5% 18.3% -682bps Profit After Tax 25.07 (2.39) - PAT Margin % 8.6% - - Earning
Slide 23: Pharma Product Mix – FY25
Pharma Product Mix – FY25 Geographies Products Shareholders’ Debt Fixed Assets Working Capital 38% Funds Africa* 45% Branded LATAM** 55% Generics 62% Dosage Forms Therapeutic Areas 12% Tablets Antibiotics 35% 4% Injectables Analgesic 17% 43% Liquids Anti-malaria Capsules Others 13% Others 15% 16% 6%
Slide 24: Core Strategy: Enter, Expand & Excel
Core Strategy: Enter, Expand & Excel Balaxi in 2020: Business Consolidation Presence across Angola, Guatemala and Dominican Republic Effective and efficient supply chain model consisting of 38 warehouses and a fleet of owned vehicles Balaxi in 2021-24: Expansion into New Geographies Aim to cap
Slide 25: Thank You
Plot No. 409, H.No. 8-2-293, 3rd Floor Maps Towers, Jubilee Hills, Road No:81,Hyderabad. Telangana CIN: L25191TG1942PLC121598 Company Investor Relations contact Sunny Purohit +91-40-2355-5300 sunny@balaxi.com www.balaxipharma.in BALAXI Thank You BALAXI:IN
Balaxi Pharmaceuticals — Q2 FY26 Earnings Presentation on 6ix